18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer

Official Title

A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)


The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiation therapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer. In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiation therapy treatment

Trial Description

Primary Outcome:

  • Number of patients with lung cancer using the PET tracer FAZA to image primary tumour hypoxia prior to treatment with radiation therapy
  • Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake
Secondary Outcome:
  • Proportion of the volume of injected FAZA tracer taken up in the tumour prior to treatment with radiation therapy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society